Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
Mesoblast Corporate Update and Financial Results Webcast
06:01pm, Wednesday, 02'nd Jun 2021
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss ope
Strength Seen in Mesoblast Limited (MESO): Can Its 6.1% Jump Turn into More Strength?
11:16am, Monday, 03'rd May 2021
Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do
Why Mesoblast Limited Stock Is Jumping Today
04:06pm, Friday, 30'th Apr 2021
The company announced positive results from a clinical trial.
MESO Stock: From $7.22 To $8.99 Explanation
12:09pm, Friday, 30'th Apr 2021
The stock price of Mesoblast Limited (Nasdaq: MESO) increased from $7.22 to a day high of $8.99 during intraday trading this morning. This is why it happened.
Mesoblast Shares Rise As Remestemcel-L Cuts Mortality In Patients Below 65 Years With COVID-19 Related Respiratory Distress
09:21am, Friday, 30'th Apr 2021
Mesoblast Limited (NASDAQ: MESO) has announced 60-day results from the randomized controlled trial of remestemcel-L in COVID-19 patients with moderate/severe acute respiratory distress syndrome (A
Appendix 4C Quarterly Activity Report
08:47pm, Thursday, 29'th Apr 2021
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021 Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2021
Mesoblast Corporate Update
07:08pm, Thursday, 29'th Apr 2021
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a
Mesoblast Operational Highlights and Upcoming Milestones
07:54pm, Tuesday, 30'th Mar 2021
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Compa
BioCardia Is Super Cheap With Multiple Shots On Goal
01:57pm, Thursday, 25'th Mar 2021
BioCardia Is Super Cheap With Multiple Shots On Goal
Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
08:03pm, Monday, 08'th Mar 2021
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completi
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics (Journal
Why Mesoblast Limited Is Rising Today
01:32pm, Thursday, 11'th Feb 2021
One of its pipeline candidates achieved great results in a late-stage clinical study.
Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study
05:41am, Thursday, 11'th Feb 2021
Positive results from Mesoblast Limited's (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company's shares higher in the premarket after an announcement
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3
Mesoblast Corporate Update
05:35pm, Wednesday, 10'th Feb 2021
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a c
